Table 2 Stratified analysis of OS meta-analysis results via univariate analysis
Factor for stratification | No. of Cohorts | No. of Cases | No.of Low AAPR | N. of High AAPR | Pooled Data | Test for Heterogeneity | |||
|---|---|---|---|---|---|---|---|---|---|
HR | 95%CI | P value | I2 (%) | P value | |||||
Overall calculation | 20 | 5921 | 2495 | 3426 | 2.14 | 1.83–2.51 | < 0.001 | 62.2 | 0.000 |
Year of publication | |||||||||
 After 2019 | 14 | 4077 | 1491 | 2586 | 2.20 | 1.85–2.63 | < 0.001 | 43.0 | 0.044 |
 Before 2019 | 6 | 1844 | 1004 | 840 | 2.02 | 1.50–2.71 | < 0.001 | 78.9 | 0.000 |
Cancer site | |||||||||
 Liver cancer | 5 | 997 | 479 | 508 | 1.96 | 1.37–2.80 | < 0.001 | 75.4 | 0.003 |
 Lung cancer | 5 | 1522 | 736 | 786 | 2.03 | 1.52–2.70 | < 0.001 | 67.1 | 0.016 |
 Others | 10 | 3412 | 1280 | 2312 | 2.32 | 1.92–2.80 | < 0.001 | 25.9 | 0.205 |
Sample size | |||||||||
  ≥ 224 | 11 | 4417 | 1873 | 2544 | 2.06 | 1.64–2.58 | < 0.001 | 69.2 | 0.000 |
  < 224 | 9 | 1504 | 622 | 882 | 2.24 | 1.86–2.71 | < 0.001 | 35.9 | 0.131 |
Cut-off value for AAPR | |||||||||
  ≥ 0.487 | 7 | 2931 | 1457 | 1474 | 2.25 | 1.75–2.88 | < 0.001 | 44.6 | 0.094 |
  < 0.487 | 13 | 2990 | 1038 | 1952 | 2.10 | 1.72–2.56 | < 0.001 | 67.0 | 0.000 |
Study design type | |||||||||
 Prospective | 1 | 390 | 212 | 178 | 4.76 | 2.56–8.33 | < 0.001 | – | – |
 Retrospective | 19 | 5531 | 2283 | 3248 | 2.05 | 1.77–2.37 | < 0.001 | 55.8 | 0.002 |
Treatment strategy | |||||||||
 Resection | 11 | 3936 | 1630 | 2306 | 2.20 | 1.95–2.50 | < 0.001 | 47.9 | 0.038 |
 Others | 9 | 1985 | 865 | 1120 | 1.64 | 1.46–1.86 | < 0.001 | 60.2 | 0.010 |
HR source | |||||||||
 Crude | 16 | 5049 | 2287 | 2762 | 2.14 | 1.85–2.47 | < 0.001 | 40.4 | 0.053 |
 Estimated | 4 | 872 | 208 | 664 | 2.21 | 1.42–3.44 | < 0.001 | 79.2 | 0.001 |
Follow-up interval | |||||||||
  ≥ 5 years | 11 | 3385 | 1171 | 2214 | 2.36 | 1.81–3.06 | < 0.001 | 70.1 | 0.000 |
  < 5 years | 9 | 2536 | 1324 | 1212 | 2.01 | 1.66–2.42 | < 0.001 | 51.8 | 0.035 |